| Authors | Countries | Type of study | Sample (N) | K13 mutations |
| Somé et al., 2016 | Burkina Faso | clinical study | 244 | C469C (2), Y493Y (1), G496G (1), V589V (1) |
| Ogouyemi-Hounto et al., 2016 | Benin | Cross-sectional | 108 | No detectable polymorphisms |
| Dieye et al., 2016 | West Africa | Cross-sectional | 463 | No mutations for Kelch 13 (K13) |
| Dorkenoo et al., 2016 | Togo | Cross-sectional | 523 | K13 propeller domain, only 9 (1.8%) mutations were reported. |
| Boussaroque et al., 2015 | Senegal | Cross-sectional | 103 | N554H, Q613H, and V637I in K13 region (5.5%) |
| Taylor et al., 2015 | Subsaharian Africa | 1100 | P553L for Kenya (0.53) and Malawi (0.59); 15 coding mutations and 12 novel mutations | |
| Torrentino-Madamet et al., 2014 | Senegal | Cross-sectional | 138 | T149S (6.3%) and K189T (42.2%), (N) or two (NN) asparagine insertion at the codon 142 (4.7% and 6.3%, respectively) |
| Issaka et al., 2013 | Niger | Experimental | 89 | Parasites remained highly susceptible to new (dihydroartemisinin, lumefantrine, pyronaridine, and piperaquine) |
| Ibrahim et al., 2009 | Niger | Cross-sectional | 92 | The pfATPase6S769N, candidate mutation of resistance to artemisinin was not found. However the pfATPsaeA623E mutation was found in 4 % of samples |
| Kaddouri et al., 2008 | Mali | Cross-sectional | 96 | No decreased susceptibility to dihydroartemisinin or lumefantrine was detected |